UBS lowered the firm’s price target on Elevance Health (ELV) to $400 from $425 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $332 from $320 at Deutsche Bank
- Elevance Health price target lowered to $396 from $414 at Guggenheim
- Elevance Health Earnings Call Flags Reset Before Rebound
- Elevance Health sees FY26 operating cash flow ‘at least’ $5.5B
- Elevance Health reports Q4 adjusted EPS $3.33, consensus $3.09